Abstract
Over the past 5 years, the adenosine A2A receptor (A2AR) is emerging as an attractive therapeutic target for modulating brain injury in a variety of animal models of neurological disorders including stroke. The evidence we have to date indicates that both adenosine and A2A antagonists are neuroprotective in ischaemic brain injury. From drug development perspective, administering A2A antagonists in association with inhibitors of adenosine kinase may represent a novel strategy for treating stroke. Despite the well-documented neuroprotection by A2AR antagonists, the mechanism by which A2ARs affect brain injury remains largely unknown. In this section, we also summarize the experimental evidence for A2AR modulation of glial function as possible contribution to the modulation of brain injury. In vitro and in vivo studies reveal that in response to local neuroinflammation following brain insults, time-dependent, inflammatory signal-mediated induction of the A2AR in glial cells (particularly microglial cells) make this cell type particularly sensitive to A2AR modulation of brain injury. Furthermore, in contrast to the generally held view that the A2AR exerts predominantly anti-inflammatory effects (based upon studies in peripheral organs), the A2AR modulation of neuroinflammation may differentially affect the outcome of brain injury, depending on the nature of brain insults. Thus, in association with their ability to reduce brain injury, inactivation of the A2AR in most models and activation of A2AR in some cases have been shown to attenuate brain inflammation through control of the proliferation and production of proinflammatory cytokines,
Keywords: Adenosine, adenosine A2A receptor, neuroprotection, ischemia, neuroinflammation, excitoxicity, microglia, astrocytes, bone marrow derived cells
Current Pharmaceutical Design
Title: Modulation of Ischemic Brain Injury and Neuroinflammation by Adenosine A2A Receptors
Volume: 14 Issue: 15
Author(s): Jiang-Fan Chen and Felicita Pedata
Affiliation:
Keywords: Adenosine, adenosine A2A receptor, neuroprotection, ischemia, neuroinflammation, excitoxicity, microglia, astrocytes, bone marrow derived cells
Abstract: Over the past 5 years, the adenosine A2A receptor (A2AR) is emerging as an attractive therapeutic target for modulating brain injury in a variety of animal models of neurological disorders including stroke. The evidence we have to date indicates that both adenosine and A2A antagonists are neuroprotective in ischaemic brain injury. From drug development perspective, administering A2A antagonists in association with inhibitors of adenosine kinase may represent a novel strategy for treating stroke. Despite the well-documented neuroprotection by A2AR antagonists, the mechanism by which A2ARs affect brain injury remains largely unknown. In this section, we also summarize the experimental evidence for A2AR modulation of glial function as possible contribution to the modulation of brain injury. In vitro and in vivo studies reveal that in response to local neuroinflammation following brain insults, time-dependent, inflammatory signal-mediated induction of the A2AR in glial cells (particularly microglial cells) make this cell type particularly sensitive to A2AR modulation of brain injury. Furthermore, in contrast to the generally held view that the A2AR exerts predominantly anti-inflammatory effects (based upon studies in peripheral organs), the A2AR modulation of neuroinflammation may differentially affect the outcome of brain injury, depending on the nature of brain insults. Thus, in association with their ability to reduce brain injury, inactivation of the A2AR in most models and activation of A2AR in some cases have been shown to attenuate brain inflammation through control of the proliferation and production of proinflammatory cytokines,
Export Options
About this article
Cite this article as:
Chen Jiang-Fan and Pedata Felicita, Modulation of Ischemic Brain Injury and Neuroinflammation by Adenosine A2A Receptors, Current Pharmaceutical Design 2008; 14 (15) . https://dx.doi.org/10.2174/138161208784480126
DOI https://dx.doi.org/10.2174/138161208784480126 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs
Recent Patents on Inflammation & Allergy Drug Discovery Development and Potential Utility of Dual and Triple NK Receptor Antagonists
Current Topics in Medicinal Chemistry Recent Advances in MRI Based Volumetry and Morphometry for AD Diagnosis in Human
Current Medical Imaging The Variable Presentations of Glycogen Storage Disease Type IV: A Review of Clinical, Enzymatic and Molecular Studies
Current Molecular Medicine Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry Antioxidant Capacities of Flavones and Benefits in Oxidative-Stress Related Diseases
Current Topics in Medicinal Chemistry DNA Damage and Repair in the Brain After Cerebral Ischemia
Current Topics in Medicinal Chemistry Gene Therapy Approaches for Neuroprotection and Axonal Regeneration after Spinal Cord and Spinal Root Injury
Current Gene Therapy RNase Therapy Assessed by Magnetic Resonance Imaging Reduces Cerebral Edema and Infarction Size in Acute Stroke
Current Neurovascular Research Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets Histone Acetylation as a Potential Therapeutic Target in Motor Neuron Degenerative Diseases
Current Pharmaceutical Design Old Strategies and New Perspectives in Modulating the Endocannabinoid System
Current Bioactive Compounds Mitochondria-Targeted Antioxidant Peptides
Current Pharmaceutical Design Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases
Current Pharmaceutical Design Comparison of Status Epilepticus Models Induced by Pilocarpine and Nerve Agents - A Systematic Review of the Underlying Aetiology and Adopted Therapeutic Approaches
Current Medicinal Chemistry Involvement of Lanthanides in the Free Radicals Homeostasis
Current Topics in Medicinal Chemistry Heme Oxygenase-2 Protects Against Glutathione Depletion-induced Neuronal Apoptosis Mediated by Bilirubin and Cyclic GMP
Current Neurovascular Research Cardiopulmonary Interactions in Children with Heart Failure
Current Cardiology Reviews Neurotoxicity: The Broad Framework of Electron Transfer, Oxidative Stress and Protection by Antioxidants
Current Medicinal Chemistry - Central Nervous System Agents